Constellation Pharmaceuticals News Releases http://ir.constellationpharma.com/ Constellation Pharmaceuticals News Releases en Constellation Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-present-bmo-prescriptions-success CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha , CEO, will present at the BMO Thu, 13 Jun 2019 14:57:00 -0400 Constellation Pharmaceuticals News Releases 7391 Constellation Pharmaceuticals Presentation Highlights Enhanced EZH2 Target Engagement, Leading to Second-Generation EZH2 Inhibitor CPI-0209 http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-presentation-highlights-enhanced CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST) today announced that Dr. Jacob Stuckey , Senior Scientist at Constellation Pharmaceuticals , gave an oral presentation titled Methods for Kinetic Assessment of High Affinity EZH2 Inhibitors: Wed, 12 Jun 2019 09:00:00 -0400 Constellation Pharmaceuticals News Releases 7386 Interim Data for CPI-0610 in MANIFEST Clinical Trial Showed Signals of Clinical Activity in Myelofibrosis Patients http://ir.constellationpharma.com/news-releases/news-release-details/interim-data-cpi-0610-manifest-clinical-trial-showed-signals CPI-0610 showed signals of clinical activity, both as a monotherapy and in combination with ruxolitinib, in refractory myelofibrosis (MF) patients Patients treated with CPI-0610 exhibited improvement in spleen volume, constitutional symptoms, anemia, bone marrow fibrosis, and transfusion dependence Mon, 03 Jun 2019 09:00:00 -0400 Constellation Pharmaceuticals News Releases 7346 Constellation Pharmaceuticals to Present at Jefferies Healthcare Conference http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-present-jefferies-healthcare CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha , CEO, will present at the Jefferies Fri, 31 May 2019 11:00:00 -0400 Constellation Pharmaceuticals News Releases 7331 Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASCO to Discuss Interim Update of Data of CPI-0610 in MANIFEST Clinical Trial http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-host-analystinvestor-meeting-asco CAMBRIDGE, Mass. , May 23, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host an analyst/investor event and webcast on June 4 at 7:00 AM CDT Thu, 23 May 2019 10:28:00 -0400 Constellation Pharmaceuticals News Releases 7321 Constellation Pharmaceuticals Presents Poster on Studies of CPI-0209 in Bladder Cancer at AACR Meeting http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-presents-poster-studies-cpi-0209 CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST) today announced that Dr. Patricia Keller , Senior Scientist at Constellation Pharmaceuticals , presented a poster titled Targeting epigenetic dysregulation in bladder cancer through inhibition of Mon, 20 May 2019 07:00:00 -0400 Constellation Pharmaceuticals News Releases 7301 Constellation Pharmaceuticals Provides Interim Update of Data for CPI-0610 in ASCO and EHA Abstracts http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-provides-interim-update-data-cpi Data published in two abstracts suggest that CPI-0610 may have potential disease-modifying effects in treating myelofibrosis All ten evaluable patients experienced spleen volume reductions Improvements in symptom scores, bone marrow fibrosis, and hemoglobin levels also seen Two transfusion Thu, 16 May 2019 09:00:00 -0400 Constellation Pharmaceuticals News Releases 7291 Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-announces-first-quarter-2019 Company to present an interim update of data from the MANIFEST clinical trial of CPI-0610 at ASCO on June 3 and at EHA on June 15 Related investor event at ASCO to be held on June 4 CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. Wed, 08 May 2019 16:15:00 -0400 Constellation Pharmaceuticals News Releases 7251 Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-present-solebury-trout-class-2018 CAMBRIDGE, Mass. , April 19, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha , CEO, will be participating and Fri, 19 Apr 2019 08:00:00 -0400 Constellation Pharmaceuticals News Releases 7221 Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting http://ir.constellationpharma.com/news-releases/news-release-details/constellation-pharmaceuticals-presents-results-phase-1b-portion Clinical activity of CPI-1205 was seen in subsets of advanced metastatic castration-resistant prostate cancer (mCRPC) patients Recently initiated Phase 2 portion of ProSTAR includes randomized testing of CPI-1205 in combination with enzalutamide versus enzalutamide alone, as well as CPI-1205 in Mon, 01 Apr 2019 13:00:00 -0400 Constellation Pharmaceuticals News Releases 7211